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Umbilical cord derived mesenchymal stromal cells (UC-MSCs) are a focus for clinical translation but standardized methods for
isolation and expansion are lacking. Previously we published isolation and expansion methods for UC-MSCs which presented
challenges when considering good manufacturing practices (GMP) for clinical translation. Here, a new and more standardized
method for isolation and expansion of UC-MSCs is described. The new method eliminates dissection of blood vessels and uses
a closed-vessel dissociation following enzymatic digestion which reduces contamination risk and manipulation time. The new
method produced >10 times more cells per cm of UC than our previous method. When biographical variables were compared,
more UC-MSCs per gram were isolated after vaginal birth compared to Caesarian-section births, an unexpected result. UC-MSCs
were expanded in medium enriched with 2%, 5%, or 10% pooled human platelet lysate (HPL) eliminating the xenogeneic serum
components. When the HPL concentrations were compared, media supplemented with 10% HPL had the highest growth rate,
smallest cells, and the most viable cells at passage. UC-MSCs grown in 10% HPL had surface marker expression typical of MSCs,
high colony forming efficiency, and could undergo trilineage differentiation.The new protocol standardizes manufacturing of UC-
MSCs and enables clinical translation.
1. Introduction
The minimal criteria for defining mesenchymal stromal
cells (MSCs) were provided by the International Society of
Cellular Therapy (ISCT) MSC working group in 2006 and
updated in 2013 with guidelines for characterization of MSC
immune properties [1–4]. The physiological properties of
MSCs suggest a potential to treat diseases such as graft versus
host disease (GVHD) and Crohn’s [5–7]. In addition, there
are more than 500 clinical trials testing the safety and efficacy
of MSCs listed on ClinicalTrial.GOV [8].
In 2014, about 53% of the MSC clinical trials world-
wide used bone marrow-derived MSCs (BM-MSCs) [9].
BM-MSCs may be used as an autologous cellular product,
which is a distinct advantage over allogeneic MSC products.
However, the collection of BM is a painful, invasive proce-
dure, when compared to MSCs from umbilical cord stroma
(UC-MSCs) which is collected painlessly from tissues that are
discarded after birth. Furthermore, adult BM-MSCs have a
lower expansion potential, lower immunosuppression capa-
bility when cocultured with activated T-cells, and perhaps a
more restricted differentiation potential than UC-MSCs [10–
15].
UC-MSCs have advantages over BM-MSCs when consid-
ered as an allogeneic MSC source. These advantages include
a virtually limitless supply of starting material which is
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available for producing tissue banks for use as an allogeneic
matched product, much like umbilical cord blood banks,
the collection of umbilical cords is painless, and the cord
donors are of a consistent, young age. In vitro, UC-MSCs have
high proliferation potential, broad differentiation potential,
and improved immunemodulation properties [11, 16–18]. For
these reasons, the therapeutic potential of UC-MSCs bears
testing, and 25 clinical trials worldwide were usingUC-MSCs
as of 2014 [9].
There are “challenges” to produceMSCsmeeting require-
ments for clinical application [2, 19]. This has led to specu-
lation that MSC manufacturing capacity may not keep pace
with the number of MSC clinical studies [19, 20]. These
challenges include the lack of a standardized method for
isolating, expanding, and validating MSCs. For example,
several methods to isolate UC-MSCs from umbilical cord
stroma have been described [21] that include the tissue
explant method [22, 23], mechanical dissociation of the
cord stroma followed by enzymatic digestion [11, 23, 24],
isolation of MSCs from the entire umbilical cord including
the blood vessels [21, 22], enzymatic digestion of the tissue
immediately surrounding the umbilical blood vessels [25], or
mincing and enzymatic digestion of the stroma (Wharton’s
Jelly) without the blood vessels [24]. Several of thesemethods
require dissection of the umbilical vessels. This dissection
step increases processing time and the risk of contamination.
For this reason, the goal here was to develop an isolation
method which would decrease contamination risk and iso-
lation time and increase the yield of MSCs. In reviewing our
MSC expansion protocol, we determined that our medium
formulation containedmany ingredients and that this created
a barrier for clinical manufacturing [24]. Therefore, our
second goal was to identify a simplified medium that would
provide for robust expansion of MSCs, be xenogen-free, and
be suitable for clinical manufacturing.
2. Materials and Methods
2.1. Umbilical Cords. This research was deemed nonhuman
subjects research by the institutional review board of Kansas
State University since discarded, anonymous human tissue
with all identifying linkages broken was used (IRB #5189).
Tissue processing was performed inside a biological safety
cabinet (BSC) in a BSL2 laboratory using universal precau-
tions per Occupational Safety and Health Administration
(OHSA) recommended blood borne pathogens containment
described in 29 CFR. 1910.1030.
In a pilot study whose data is not presented here, 8
umbilical cords were used to identify optimization variables.
In the work reported here, 24 umbilical cords (11 females and
13 males) were used; umbilical cords from vaginal births or
Caesarean-section births were used.The umbilical cords were
stored in sterile tissue sample container in saline solution at
4∘C until use. In pilot work not presented here, umbilical
cords were stored for up to 5 days prior to processing to
extractMSCs; however, no parametric testing was performed
to determinewhether storage alters the quality of the product.
Here, isolations procedures were performed within 4 days
after birth. To randomize the treatment effects, we performed
no prescreening and randomly assigned cord samples (bio-
logical replicates) to each experimental variable.
2.2. Isolation Optimization Strategy. Here our previously
described protocol [24] was optimized to decrease contam-
ination risk, increase yield, and improve GMP compatibility.
For each umbilical cord (the biological unit), eight ran-
domly selected 1 cm length samples were used to test the
effect on the experimental variables identified in the pilot
work. Two to four optimization variables were evaluated
per cord using technical duplicates and the results were
averaged for each experimental variable per biological unit
for comparisons. First, we tested mechanical disruption of
the tissue using a Miltenyi GentleMACS Dissociator (#130-
093-235) using preprogrammed settings A, B, C, D, and E
(which corresponds to weakest to strongest dissociation).
Next, tissue dissociation conducted before or after enzy-
matic digestion was tested. Then, the effect of mincing the
tissue samples was compared to tissue dissociation using
the GentleMACS Dissociator. Next, the effect of filtering
using 100𝜇m cell strainers (Fisherbrand #22-363-549) and
60 𝜇m Steriflip tubes (Millipore #SCNY00060) was tested.
Lastly, the concentration of enzyme was varied to determine
the effect on yield. The technical duplicates or triplicates
were averaged for each variable per cord sample. Each
procedural optimization variable was evaluated using at least
three different cord replicates. Decision making strategy
was designed-based using process yield (more live cells) or
increasing process efficiency (reducing number of processing
steps, reducing time, or reducing contamination risk).
2.3. Final (Optimized) Isolation Method. A schematic of
the revised method is shown in Figure 1. Umbilical cords
were rinsed to remove surface blood using 37∘C DPBS
which had 1% Antibiotic-Antimycotic (Dulbecco’s Phosphate
Buffered Saline, Life Technologies #14190-250; Antibiotic-
Antimycotic, Life Technologies #15240-062). The cords were
then treated with 0.5% Betadine (Dynarex, Providone Iodine
Solution, #1416) in DPBS for 5 minutes at room temperature.
Inside the biological safety cabinet (BSC), the cord was
cut into 1 cm lengths and rinsed repeatedly with 3 volumes
of DPBS until no further surface blood could be seen.
Each 1 cm length of tissue was cut into four equal size
pieces and placed into a Miltenyi Biotech Dissociator C-Tube
(Miltenyi #130-096-334). The tissue weight was calculated by
subtracting the tare weight of the C-tube and 9mL of enzyme
solution was added. The C-tubes were placed into a Miltenyi
Dissociator, processed using program C and incubated for
3–3.5 hours at 37∘C with constant 12 rpm rotation. Follow-
ing the 3–3.5-hour incubation, the tissues were dissociated
using program B and filtered through 60 𝜇m Steriflip filter
(Millipore #SCNY00060) to remove tissue debris. The cells
were pelleted by centrifugation at 200×g for 5 minutes at
room temperature and the supernatant was discarded. The
cells were suspended in 0.5mL of growth media and 0.5mL
RBC lysing solution (Sigma’s RBC lysis solution, #R7757-
100ML) was added to remove red blood cell contamination.
The cells were mixed gently for one minute followed by
addition of 8mL of DPBS. Cells were centrifuged at 200×g
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Figure 1: A schematic of the optimized isolation method. The major steps: (a) umbilical cord selected. (b) 1 cm section prior to cutting into
4 equal pieces. (c) Cord pieces rinsed in DPBS. (d) The cord pieces inside a C-tube immersed in enzyme solution. (e) Dissociation with C-
tubes and Miltenyi Dissociator. (f) Steps following dissociation prior to plating the isolated cells. (g) The isolated cell initial plating at P0 and
subsequent expansion over multiple passages.
for 5 minutes at room temperature and the supernatant was
discarded. The cells were suspended in 1mL of media and
the number of live cells was determined using a Nexcelom
Auto 2000 Cellometer (immune cells program, low RBC)
following ViaStain AOPI (acridine orange and propidium
iodide) viability staining (Nexcelom cat. #CS2-D106-5ML).
Cells were plated at 10,000–15,000 live cells per cm2 on tissue
culture treated plastic (CytoOne 6-well plates, #CC7682-
7506).
2.4. Optimization of MSC Expansion. Our previously de-
scribed method MSC expansion medium was the standard
used for comparison. Since that medium contains more than
10 components [24], our goal was to reduce the number of
medium componentswhilemaintaining theMSC attachment
at isolation/startup and maintaining MSC expansion, CFU-
F efficiency, trilineage differentiation potential, MSC surface
marker expression, and cellular morphology similar to or
better than that standard. Here, low glucose Dulbecco’s Mod-
ified Eagle’s Medium (DMEM Life Technologies cat. #14190)
supplemented with 1% GlutaMAX (Life Technologies cat.
#35050), with 1% Antibiotic-Antimycotic, and, by volume,
with 2, 5, or 10% pooled human platelet lysate (HPL, pooled
from more than 25 outdated platelet donors, supplied by
Kansas University Medical Center diagnostic laboratory, Dr.
Lowell Tilzer, director) and 4 units/mL heparin was tested.
The cells were plated at 10–15,000 cells per cm2 in CytoOne
flat bottom tissue culture treated 6-well plates and expanded
for 5 passages. Cells were incubated and grown as a mono-
layer at 37∘C, 5% CO
2
, and 90% humidity (Nuaire AutoFlow
4950 or Heracell 150i). Once the cells reached approximately
80–90% confluence they were lifted and plated in fresh
medium. To lift the cells, the medium was removed and cells
were washed with 37∘C DPBS. The DPBS was removed and
replaced with 37∘C 0.05% trypsin-EDTA (Lifetech #25200-
056). Following a 3–5-minute incubation at 37∘C, the plates
were tapped to release cells and the enzymatic digestion was
terminated with 3 volumes of media. Cells were pelleted
at 200×g for 5 minutes at room temperature. Supernatant
was discarded and 1mL of media was used to suspend the
cells. Cells were counted using the Nexcelom Auto 2000
Cellometer and the ViaStain AOPI staining reagent using the
manufacturer’s protocol and a built-in settings. At passage,
the number of cells, percentage of live cells, cell size, and
number of hours in culture were recorded. Cells were initially
plated at a density of approximately 10,000 cells/cm2; using
this as the initial cell number and the number of cells at
harvest as the final cell number and culture time, population
doubling time was calculated using the standard formula.
At times, extra cells were frozen for later use. To freeze,
cells were cryopreserved using a 1 : 1 ratio of HPL media and
cryopreservative (Globalstem #GSM-4200) and held on ice
until transfer to a controlled rate freezing device (Mr. Frosty)
and being placed into a−80∘C freezer overnight.Thenext day,
the vials were moved to the vapor phase of liquid nitrogen for
long term storage.
2.5. CFU-F Assay. MSCs were plated at 10, 50, or 100 cells
per cm2 in duplicate in 6-well CytoOne tissue culture plates
in 2, 5, and 10% HPL enriched DMEM, as described above.
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Four cell lines were expanded 4 days in culture, prior to
fixation and methylene blue staining. Subsequent tests used
4–7 days of culture at a density of 5, 10, or 50 cells per
cm2. After the required culture period, the medium was
removed and the cells were washed with DPBS and then
fixed using 4∘C 100% methanol for 5 minutes. The cells were
washed again with DPBS, stained with 0.5% methylene blue
for 15 minutes, rinsed several times with distilled water, and
air dried. The stained colonies were counted manually at
40x final magnification. Colonies were defined as isolated
groups (clonal groups) of at least 10 cells. Colony number
was determined by averaging the number of colonies in
the technical replicates at each plating density for a given
expansion period. Colony forming efficiency was calculated
by dividing the number of plated cells by the number of
colonies.
2.6. Differentiation. Differentiation of MSCs was induced
by replacing the expansion medium with MSC differenti-
ation medium (StemPro, Life Technologies #s A10070-01,
A10071-01, and A10072-01 for adipogenic, chondrogenic, and
osteogenic differentiation) and following the manufacturer’s
protocol. After about 21 days of differentiation, the differ-
entiation medium was removed; the MSCs were washed
with DPBS, fixed with 4% paraformaldehyde for 10min, and
stained with Oil Red for analysis of adipose cells, Safranin O
for chondrogenic cells, or Alizarin Red S for osteogenic cells.
Micrographs were taken using an Evos FL Auto microscope
(Life Technologies).
2.7. Flow Cytometry. The BD human MSCs flow cytome-
try characterization kit was used for positive and negative
surface marker staining (#562245). Using the manufacturer’s
recommended protocol, MSC samples were stained with
four fluorochromes together including positive and negative
staining cocktails. The positive marker cocktail stained for
CD90, CD105, and CD73 (defined as >97% positive staining).
The negative cocktail (all antibodies were stained using a
single fluorochrome, PE) stained for CD34, CD45, CD11b,
CD19, and HLA-DR (defined as <2% positive staining). A
CD44 labeled PE antibody was used as positive control for
the negative cocktail to set the compensation and gating of
the negative cocktail. For each flow cytometry run, fluores-
cence minus one controls for each fluorochrome and isotype
controls for each antibody were used for compensation and
nonspecific fluorescence analysis. Samples were washed with
1% BSA solution before and after staining. A FACScalibur
(BD Biosciences) was used for flow cytometry and analysis
was conducted using FCS software. Negative staining gate of
the isotype control was set at 1% positive staining.
2.8. Statistics. After confirmation that ANOVA assumptions
of normality and homogeneity of variance weremet, ANOVA
was used to evaluate significant differences between opti-
mization variables. If the assumptions were violated, the
dataset was transformed mathematically and again tested
to see if it met ANOVA assumptions. Hypothesis testing
was two tailed (e.g., mean 1 ̸= mean 2). After running
ANOVA and finding significant main effect(s) or interaction
terms, post hoc means testing of planned comparisons was
conducted using either the Bonferroni correction or Holm-
Sidak method. Significance was set at 𝑝 < 0.05. Data is
presented as average (mean) plus/minus one standard error.
In one case, in order to pass the normality test (Shapiro-Wilk)
an “outlier” was removed. After the outlier was removed, the
dataset passed the normality test and ANOVA determined
that there was a significant effect of HPL concentration.
SigmaPlot v.12.5 (Systat software) was used for statistics and
making of the graphs. The graphs created in SigmaPlot were
saved as EPS files and moved into a vector-based graphics
package (Adobe InDesign or Adobe Illustrator CS6) for
editing and rendering.
3. Results
3.1. Umbilical Cords. Umbilical cord from Caesarean-section
delivery (𝑛 = 17) and “normal” vaginal delivery (𝑛 = 7)
were used in this research. The biographic data of each cord
is shown in Table 1.
3.2. IsolationMethod Comparison. Note that theMSC expan-
sion comparisonwas considered for passages 1–5, and passage
0 was considered part of the isolation of MSCs. Results
obtained from our previously described method (historical
data from 27 umbilical cords [24]) and our optimizedmethod
were compared. As shown in Figure 2, the optimizedmethod
yielded on average 10 times more MSCs per cm length than
the original method and yielded MSCs in 100% of the UC
samples. Note that in pilot work where we were identifying
variables to optimize, we did fail to isolateMSCs in two cases.
But even in these cases, MSCs were isolated from the same
UC in different samples (e.g., in no cases did we suspect
that the UC did not contain viable MSCs). While we did not
test for bacterial, viral, or fungal contamination, no break in
sterility was apparent here (e.g., no frank contamination was
observed and no cultures were discarded due to contamina-
tion). Live cells per cm of length or per gram were compared
in Table 1; there was a trend for the coefficient of variation
to be less for live cells per gram. The optimized method uses
a closed processing system for tissue disruption and takes a
total of 4 hours of work time plus a 3-hour enzyme extraction
step to isolate the umbilical cordMSCs.MSC attachment was
observed within 24 hours of the isolation and proliferation
was observed in all three HPL media enrichment conditions.
As shown in Figure 2(c), during the isolation phase (P0)
UC-MSCs grew more quickly when plated in 5% or 10%
HPL enriched DMEM than UC-MSCs plated in 2% HPL
enriched DMEM. It is possible that UC-MSCs grown in 5
or 10% HPL enriched DMEM attached more quickly than
those grown in 2% HPL enriched DMEM in P0. The growth
rate difference for 2%HPL enriched mediumwas statistically
different (slower) at P0 then later passages (see Figures 2(c)
and 3(a)) and was significantly different (slower) than 5 and
10% HPL enriched media at isolation and during expansion.
3.3. MSC Expansion Comparison. Note that the MSC expan-
sion comparisonwas considered for passages 1–5, and passage
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Figure 2: Effect of various experimental variables on UC-MSCs isolation. (a)The newmethods average cell number per cm of umbilical cord
isolated, compared to the old cell number isolated per cm (∗∗means 𝑝 < 0.001). (b) Comparing different experimental variables. Significant
difference observed in Caesarean-section delivery versus vaginal delivery (∗ means 𝑝 < 0.05). (c) Population doubling time for passage 0
(initial isolation) or passage 1 (first passage of expansion phase). ∗ represents 𝑝 < 0.05 for 2% hpl media compared to 5% and 10% media.
† represents 𝑝 < 0.05 for the passages (P0 compared to the P1).
0 was considered part of the isolation of MSCs. UC-MSCs
were expanded for passages 1–5 here. UC-MSCs were evalu-
ated in 3 different growth conditions: DMEM supplemented
with 2% HPL, 5% HPL, or 10% HPL. A two-way ANOVA
(main effects HPL level and expansion over time) found a
significant main effect (HPL concentration) on attachment
and expansion. In post hoc testing, we found significantly
more cells—about 30% more were obtained when cells were
expanded in 10% HPL enriched DMEM medium compared
to 5% HPL enriched medium (9.4 × 105 ± 6.2 × 104 cells
per cm2 versus 6.6 × 105 ± 3.8 × 104 for 5% HPL enriched
medium (Figure 3(b)). Similarly, post hoc testing showed
significantly shorter population doubling times when MSCs
were expanded in 10% HPL (32.4 ± 2.5 hours), compared
to 40.7 ± 4.1 hours for 5% HPL and 100.9 ± 14.8 hours
for 2% HPL enriched medium (shown in Figure 3(c)). As
shown in Figure 3(d), MSCs grown in 10% HPL enriched
DMEM averaged 17% smaller than those grown in 2% HPL
(14.7 ± 0.2 𝜇m versus 17.6 ± 0.4 𝜇m) and 10% smaller than
cell grown in 5% HPL enriched medium (on average over
5 passages, 16.1 ± 0.3 𝜇m). The trends in MSC size across
HPL medium conditions became noticeable after the second
passage (Figure 3(e)). HPL medium enrichment affected the
viability of the cells noted at passage (see Figure 3(c)). Subtle
but significant differences were found in viability at passage
between the three medium conditions: MSCs in expanded
in DMEM supplemented with 10% HPL had higher viability
than those grown in DMEM supplemented with 2% HPL
(92.2 ± 0.9% versus 84.9 ± 1.7%) and 5% HPL supplemented
medium had significantly greater viability than 2% HPL
medium (90.4 ± 0.9%; see Figure 3(c)).
The theoretical cell yield was calculated assuming the
entire umbilical cord was isolated and expanded in each
medium condition to passage 5. As shown in Figure 3(f), it
was estimated that the total yield might exceed 1012 MSCs
(a trillion cells) at passage 5 for UC-MSCs expanded in 10%
HPL supplemented medium and exceed 1011 MSCs for UC-
MSCs expanded in medium supplemented with 5% HPL
(Figure 3(f)).
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Figure 3: Effect of HPL concentration on expansion. (a–d) UC-MSC (𝑛 = 6) expansion results combined for passages 1–5. (a) Population
doubling times for the 3 media conditions. (b) Number of cells counted at passage for each media condition. (c) Cell viability at passage
for each media condition. (d) The average size of the cell for each media condition at passage. (e) Cell size over 5 passages for each media
condition. (f) The theoretical yield if an entire umbilical cord was isolated and grown to confluence at each passage. ∗ means 𝑝 < 0.05 and
∗∗means 𝑝 < 0.001.
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3.4. Evaluation of UC-MSC Characteristics. Sex of the donor
had no effect on number of MSCs isolated (Figure 2(b)),
or the estimated number of MSCs obtained after expansion
(data not shown). In contrast, a significant increase in the
number of cells isolated was found for UC-MSCs isolated
from normal vaginal delivery compared to those collected
following Caesarean-section delivery (see Figure 2(b)).
3.5. Colony Forming Unit-Fibroblast (CFU-F) Data is Pre-
sented as a Normalized Unit: Colony Forming Efficiency (CFE;
CFE=Number of Plated Cells Divided byNumber of Colonies).
As shown in Figure 4(e), the concentration of HPL supple-
mentation had no effect on CFE at 10 cells/cm2 (100 cells
per well of a 6-well plate) after 4 days of culture. In contrast,
when plated at a density of 50 cells per cm2 and 4 days of
expansion in culture, 10% HPL supplementation resulted in
an increased colony forming efficiency compared to 2 and
5% HPL: 2–4 MSCs were needed to form a colony when
plated inmedium supplemented with 10%HPL (Figure 4(e)).
As seen in Figure 4(e) and as previously reported [26, 27],
plating density affects colony forming efficiency and higher
efficiency is found at lower plating density. Therefore we
determine whether higher efficiency would be found at
plating density below 10 cells/cm2 after plating in HPL. The
highest colony forming efficiency was found when MSCs
were plated at 5 cells/cm2 for 6 days (50 cells per well of
a six-well plate); in medium supplemented with 10% HPL:
on average one out of two MSCs formed a colony (see
Supplemental Figure 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2016/6810980).
3.6. Differentiation. MSCs isolated and expanded using the
optimized method undergo differentiation to the three mes-
enchymal lineages, bone, cartilage, and fat after exposure
to differentiation medium conditions for 3 weeks. Figure 4
shows MSCs differentiated to fat and chondrogenic and
osteogenic lineages following closed isolation method and
expansion to passage 5 in 10% HPL supplemented DMEM.
Exposure to adipogenic differentiation medium resulted in
formation of lipid droplets in MSCs that stained with Oil
Red (Figure 4(a)). Exposure to osteogenic differentiation
conditions resulted in calcium deposits formed within MSCs
which stained with Alizarin Red S (Figure 4(b)). Cartilage-
like tissue formation was observed in clusters of cells after
exposure to differentiation medium as indicated by gly-
cosaminoglycan staining by Safranin O for chondrogenic
cells (Figure 4(c)).
3.7. Flow Cytometry. Flow cytometry was used to analyze the
surface marker expression in 5 MSC lines following isolation
using the closed processing protocol and expansion using
the 10% HPL supplemented DMEM for 5 passages. High
expression (>95% positive) for surface markers CD73, CD90,
CD105, and CD44 was observed (Figure 5 for representative
results, Supplemental Table 1 for all flow cytometry data). Low
surface maker expression (<0.5% positive) was observed for
CD34, CD45, CD11b, CD19, and HLA-DRT (Supplemental
Table 1). To evaluate the effect of freezing and thawing
MSCs on surface marker expression, four MSCs lines were
evaluated before and after a freeze/thaw cycle. No significant
differences were found in surface marker expression between
frozen/thawed and never frozen MSCs in surface marker
expression (Supplemental Table 2).
4. Discussion
The acceleration of stem cell and regenerative medicine
clinical trials, and MSC trials in particular, has produced
a renewed effort to standardize production and character-
ization of MSCs in GMP-compliant SOPs. Umbilical cord
MSCs have a number of advantages which suggest that they
might be an important source for allogeneicMSCs for cellular
therapy, and, as indicated by trends in MSC clinical trials
worldwide, this MSC source is a needed one.
In order to develop an SOP for GMP production of UC-
MSCs, we identified limitations in our previously described
method for UC-MSC isolation and expansion that repre-
sented barriers for GMP production. First, our previous
isolation method required a lengthy dissection step and the
opening of the umbilical cord and manually removing the
vessels prior to mincing the Wharton’s jelly was time con-
suming and increased contamination risk. Here, we sought
to reduce processing time and reduce contamination risks.
We reasoned that a standardizedmethod for liberatingMSCs
from the Wharton’s jelly may produce a more homogenous
product. Second, the previously describedUC-MSCmedium,
which was originally described by Catherine Verfaillie’s lab
for expansion of MAPCs, is complicated with more than
10 components and it contained 2% FBS, a xenogeneic
product [28]. We sought to identify a simplified medium
that could be free of xenogeneic materials and contain
fewer components. We tested human platelet lysate (HPL)
enriched medium. Previous work indicated that HPL could
be produced in a GMP-compliant format and has been
reported to produce good expansion of MSCs [29–31]. Here,
we found that 5 or 10% HPL enrichment vastly improved
MSC expansion in the P0 (initial isolation). Furthermore,
we found robust expansion over passages 1–5. Therefore, use
of HPL-enriched medium eliminated two barriers to GMP-
compliant manufacturing of UC-MSCs. However, using a
pooled human blood product is not without certain risks,
they have been somewhat mitigated (discussed below). Due
to the sample to sample variability, pooling of platelet lysate
is essential to produce a uniform product [32]. For example,
human pathogens that escape screening by the providers
may contaminate HPL samples. One possible way to address
this risk would be to inactivate pathogens in HPL [33].
We did not inactivate pathogens in our pooled HPL, but
the repeated freeze-thaw process followed by the filtration
through a 0.2 um filter should remove all potential bacteria
and parasites. While gamma irradiation is something that
may be considered to lower viral risk, the blood products used
were obtained from a blood bank for clinical use and thus had
met all existing blood screening safety measures.
Here, 1 cm sections of cord were used to optimize the
protocol. The one cm length sections of umbilical cord
provided enough cells for isolation and expansion, and many
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Figure 4: Differentiation and colony forming unit fibroblast (CFU-F) results for the characterization of UC-MSCs. (a) After adipogenic
differentiation, MSCs were stained with Oil Red which binds to lipid droplets (20x objective magnification; scale bar = 200 micrometers).
(b) After osteogenic differentiation, MSCs were stained with Alizarin Red S which binds to calcium deposits. (c) After chondrogenic
differentiation, MSCs stained with Safranin O which binds to glycosaminoglycans in cartilage ((b) and (c) at 10x objective magnification;
scale bar = 400 micrometers). (d) UC-MSCs in normal growth conditions (control) phase contrast micrograph at 4x objective magnification.
(e) CFU-F efficiency was calculated by dividing the number of plated cells by the number of CFU-F colonies observed. Panel (e) shows colony
forming efficiency versus human pooled platelet lysate (HPL) concentration in medium (2, 5, or 10% HPL) after plating at 5 (black bars) or
10 (gray bars) cells per cm2 and 4 days in culture.
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Figure 5: Histograms of flow cytometry; blue solid filled overlay represents the test sample; red diagonal line filled overlay represents the
isotype control. For each histogram the negative gate (red bar) was set for inclusion of 99% of the isotype. Percentages shown in histograms
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Stem Cells International 11
technical replicates were available from one cord which
allows multiple experimental variables to be examined in
each cord (the biological variable). We assumed that a
randomly selected, one cm length of cord would adequately
represent the umbilical cord (e.g., that cellular distribution
and umbilical cord extracellular matrix are homogenous).
This assumption was not validated by us, nor do we know
of any investigation that supports or denies this assumption.
Umbilical cords display tremendous biological variation in
density (weight per unit length), diameter, and physical
mechanical properties perhaps due to the amount of extracel-
lular matrix surrounding the vessels (see Table 1). The gram
per cm measurements vary within each technical replicate
from a single cord and between different umbilical cords,
too.This indicates the importance for multiple biological and
technical replicates when performing optimization testing
using umbilical cords. The number of cells varied consid-
erably between each umbilical cord as did the density and
amount of extracellular matrix. Thus the biological variation
limits the ability to manufacture a standard cellular therapy
product. For example, does the physiology of MSCs vary
between umbilical cords and how canwe optimize the clinical
effect of MSCs? We have assumed that the cells isolated
after an initial passage are similar in physiology, but this
assumption will require more assaying to confirm.
Several protocols for isolation of MSCs from different
parts of the umbilical cord have been published [26, 34, 35].
These protocols require dissection of different portions of
the umbilical cord and a variety of methods to enrich MSCs
from the primary isolation population. This contributes to
variation in the number of cells in the primary isolation and
their ability to undergo expansion in culture. We did not
observe frank differences in the population of MSCs isolated
following their extraction from Wharton’s jelly versus those
isolates following disruption of the entire 1 cm cord fragment.
We found that extraction of the entire 1 cm length using the
methods outlined here gave a>10-fold increase in the number
of input cells for the primary culture.We attribute the reduced
manipulation of the tissues (elaborate dissection negatively
affects the attachment and expansion) and the more efficient
removal of red blood cell contamination (blood negatively
affects the viability, attachment, and expansion of MSCs) to
the improved extraction and expansion efficiency.
Previously we used “cord length” measurement for com-
parisons of yield between cords. Here, we tracked both
length and weight to determine whether either proved to
be a better predictor of cell yield in initial isolation. The
variation between umbilical cords for both length and weight
is represented in Table 1. As seen in Table 1, weight was
a more reliable measurement compared to cord length.
Additional work is needed to determine differences between
the predicted total cell yield from an umbilical cord and the
estimated value. We have not processed cells from an entire
umbilical cord and therefore cannot confirm the accuracy of
these estimates. Our current method is readily scaled up, and
so this information is forthcoming.
The increase in cell numbers from the optimized protocol
may be attributed to the faster processing and reduced dis-
section when isolating the MSCs. By not removing the blood
vessels, the optimized method is a significant departure from
our previously described method. Therefore, this casts into
doubtwhether the same cell population has been isolated, and
whether theMSCs obtained using the optimizedmethods are
similar or different from those obtained using the previous
methods. As mentioned in Section 1, several different meth-
ods for obtaining MSCs from the umbilical cord have been
described, and it is unclear whether each isolates the same
cells. Our data does not directly address this question, but
we demonstrate here that following evaluation of 5 umbilical
cord MSC isolates; the cells isolated from the optimized
methods conform to ISCT criteria for MSCs [4].
As far as we know this paper is the first to demonstrate
a difference betweenMSC isolation efficiency from umbilical
cords derived from vaginal births versus Caesarean-section
births. Vaginal birth umbilical cords had more cells per
after isolation by approximately 41% (Figure 2(b)). Prior to
observation, we preferred to use Caesarean-section umbilical
cords for MSC isolation because we assumed that surgi-
cal collection would have a reduced contamination risk
compared to cord collected following the passage through
the birth canal. During this study we found no differences
in contamination from either vaginal birth or Caesarean-
section umbilical cords. Similar to our observations about
MSCs from vaginal versus Caesarean-section cords, the
volume of umbilical cord blood collected is decreased by
vaginal birth over Caesarean-section birth [36, 37]. We did
not see a sex difference between the number of cells isolated
or MSC expansion rate or number. Enzymatic digestion
using a high concentration of digestive enzymes tended to
have higher yield at isolation (Figure 2(b)). Visually, higher
concentration of enzyme samples appeared to have less debris
when compared at initial plating compared to lower enzyme
concentration.
After the initial plating of cells during the isolation
protocol, there is a delay in cell attachment. Attachment to
the substrate is a defining characteristic of MSCs and appears
to be necessary for MSCs expansion. We noted that after
the isolation of MSCs, in passages 1–5, MSCs attach and
begin to expand within 24 hours of plating. In contrast, the
time to reach the confluence for the isolation and initial
passage is significantly impacted by delays in attachment.
Here, we included the P0 data with the isolation ofMSCs and
considered passages 1 through 5 for the expansion phase of
MSC characterization. We noticed a trend that when there
was a higher viability at the initial isolation, the cells attached
better and expanded more rapidly. In our prior work, cell
viability was not recorded at the initial isolation. Here, the use
of the Nexcelom and ViaStain AOPI viability assay provided
a quantitative method and gave more consistent results than
trypan blue and manual counting using the haemocytometer
(which is how we counted cells, previously). Automated cell
counting lends itself to optimization and producing SOPs.
When considering the production of a public bank of
cord samples, freezing the primary isolates at P0 → P1 is
likely to be a necessity. Others have reported this affects cells
surface marker expression or viability [38]. For that reason,
we evaluated surface marker expression in never frozen
cells and in cells subjected to a freeze/thaw cycle. The flow
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cytometry analysis did not show a difference in surface
marker expression between fresh cells (e.g., those never
frozen) and cells frozen and thawed cells for four umbilical
cord MSCs lines. Future testing is needed to confirm that
these results stand up with a larger sample size. Clinical trials
will require the freezing of cells for use, the use of fresh
cells in clinical trials is not feasible when considering the
rigorous quality control and release testing that must be done
to determine if these cells meet the standards for clinical use.
Here, human platelet lysate enriched media at three dif-
ferent concentrations (2%, 5%, and 10%) was used to analyze
the effect on the initial isolation (P0) and growth of the
MSCs for passages 1–5. We evaluated MSCs through passage
5 to characterize expansion potential. We observed that P0
to P1 expansion exhibited the highest amount of variation
in growth rate (see Figures 2(c) and 3(a)). Results from six
umbilical cords did not show a difference between passages
1–5 for population doubling time, number of cells at passage,
and viability at passage (data not shown). However, the three
media conditions did affect these variables. Enrichment with
2% HPL enriched medium was significantly different than
5% and 10% HPL enriched media for population doubling,
cell size, cell numbers, and viability. Enrichment with 2%
HPL had slower population doubling, fewer cells at passage,
larger cells, and a lower percentage of viable cells at passage.
We observed a trend associated with better results for these
measurements as HPL enrichment in the medium increased.
For this reason we chose 10% as the new standard media
condition to be used to grow the UC-MSCs. Cell size for
the UC-MSCs was a variable we did not expect to vary
significantly between the different media conditions, but we
observed a significant difference in cell size with higher
HPL concentration. We noticed a trend for cell size to
initially increase after the first passage and then decrease
over subsequent passages in all media conditions (Figures
3(d)-3(e)). We cannot explain this observation. Further work
is needed to assess whether cell size is affected by passage,
since we have previously observed that senescent cells are
larger, and because we would expect an increase in cellular
senescence with passage. If the contrary is true, for example,
the fact that more rapidly dividing cells are smaller, then the
cell size data could support our conclusion that 10% HPL
is the optimal growth condition for the UC-MSCs. Previous
work had indicated that smallerMSCs with a rapidly dividing
phenotype could be identified by plating at a density of 3
cells per cm2 [39]. Here, we did not evaluate the effect of
plating density on proliferation. Future work should evaluate
the interaction between plating density and 10% HPL media
to optimize manufacturing efficiency.
MSC characterization was done by assessing cell surface
markers with flow cytometry, CFU-F, and differentiation
capacity. All five cell lines we analyzed with flow cytometry
had high levels of the surfacemarkers known to be associated
with MSCs. The high percentage of positive cells (>95%) is
comparable to the previously published method [24]. These
results suggest a homogenous cell population was isolated
even though the blood vessels were not removed for the
isolation step. Differentiation ability was assessed in the same
five cell lines and all display trilineage differentiation capacity.
The capacity for adipogenic differentiation was analyzed by
Oil Red O staining for lipid droplet accumulation within
the differentiated cells cytoplasm. Analysis showed multiple
lipid droplets forming within a large number of the cells
(Figure 4(a)). Cell death did occur during the time to differ-
entiate, leading to space between the adipogenic cells in the
figure. Osteogenic differentiation was stained with Alizarin
Red S to analyze calcium deposit formation. Staining was
observed in calcium deposits on the cells and within the cells
as seen in Figure 4(b). Chondrogenic differentiated cells were
stained with Safranin O to assess if cartilaginous associated
with glycosaminoglycan. This differentiation yielded circular
colonies, often remaining adhered to the plate and they
robustly stained for SafraninO.Typically histological sections
of microcolonies are used to assess chondrogenic lineage
differentiation. Our results indicate this is not necessary
when small colonies of cell remain adherent (Figure 4(c)).
Although the results are not quantified, the quality of the
staining and duplication between multiple lines provides
good evidence that MSCs isolated and expanded by the new
method have robust trilineage differentiation potential.
Colony forming unit fibroblast (CFU-F) efficiency ana-
lyzed self-renewal potential of UC-MSCs. Compared to
previous research for UC-MSCs expanded in 21% oxygen,
fewer cells were needed to form a colony using the method
described here, suggesting a higher colony forming efficiency
[27]. We considered the 10 cells per cm2 a more reliable
measure for the effect of HPL concentration due to difficulty
counting cells at 50 cells per cm2. The fast growth rate for
the 10% HPL enriched medium made our previous CFU-
F protocols unreliable because the plates grew too fast. We
tested growth conditions for measuring colony forming effi-
ciency by analyzing days from plating versus colony counts.
We found the number of cells to form colonies decreasedwith
each day of growth; the exception was 50 cells per cm2 which
increased. The highest CFU-F efficiency was for 5 cells per
cm2 cells grown for 6 days. We determined using both 10 and
50 cells per cm2 yield consistent data for CFU-F. The self-
renewal data (colony forming efficiency) is important when
estimating the expansion potential of a MSC line. Higher
CFU-F efficiencies are associated with MSC lines displaying
a more robust growth potential. Determining the method
for analyzing CFU-Fs in these fast growing cells allows for
analysis of growth potential for future research using UC-
MSCs.
Here we provide a new, optimized method to isolate and
expand UC-MSCs.When compared to our previous method,
an increase in total MSC yield at the initial isolation of more
than 10 times was obtained, and less time is needed to isolate
MSCs from the umbilical cord. Additionally, this method
reduces the overall expansion by reducing the amount of
population doubling needed to meet our production target
of 2–10 billion cells per batch. The method uses closed
system for initial isolation with minimal dissection of the
cord and, thus, reduces contamination risk, while simul-
taneously reducing processing time. The method uses a
simplified (5 component), xenogen-free medium that can
be upgraded to GMP-compliant components for scale-up.
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Characterization of MSCs produced using this optimized
processing protocol and simplified medium included in
vitro expansion, colony forming efficiency, and trilineage
differentiation to osteogenic, chondrogenic, and adipogenic
lineages, and surface marker expression by flow cytometry
indicates that MSCs were produced by this method. Further
work is needed to confirm that MSCs isolated and expanded
using this method will perform in vivo as a cellular therapy.
We are developing an in vivo model to test the potency
of MSCs which may serve as suitable assay to compare
the potency of various manipulations such as “priming” or
licensing of MSCs. Taken together, this work will speed
clinical translation of UC-MSCs by providing the basis of
chemistry and manufacturing controls (CMC) portion of an
investigation of new drug application (IND).
5. Conclusion
The methods we developed for isolation and expansion of
UC-MSCs address some challenges to translation to clinical
use. We report an increased MSC yield for vaginal births
compared to Caesarean-section births. The new isolation
method provides the necessary cell yield for banking and
uses a closed system that can be easily scaled up and
expansion media supplemented with 10% HPL had the best
growth rate. These results provide improvements which may
support GMP manufacturing of UC-MSCs. To complete the
validation of this newmethod, functional testing for immune
modulation or regenerative potential testing is needed.
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